当前位置: X-MOL 学术Arch. Pharm. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Synthesis of new arylazopyrazoles as apoptosis inducers: Candidates to inhibit proliferation of MCF‐7 cells
Archiv der Pharmazie ( IF 4.3 ) Pub Date : 2020-09-13 , DOI: 10.1002/ardp.202000214
Magda M F Ismail 1 , Dalia H Soliman 1 , Rehab Sabour 1 , Amel M Farrag 1
Affiliation  

New 4‐arylazo‐3,5‐diamino‐1H‐pyrazole derivatives substituted in the 4‐aryl ring with the acetyl moiety were designed and synthesized. The antiproliferative activity of the novel arylazopyrazoles was examined against the MCF‐7 cell line. Among all target compounds, 8b (IC50 3.0 µM) and 8f (IC50 4.0 µM) displayed higher cytotoxicity as compared with the reference standard imatinib (IC50 7.0 µM). Further studies to explore the mechanism of action were performed on the most active hit of our library, 8b, via anti‐CDK2 kinase activity. It demonstrated good inhibitory effects for CDK2 (IC50 0.24 µM) with 62.5% inhibition, compared with imatinib. The cell cycle analysis in the MCF‐7 cell line revealed apoptosis induction by 8b and cell cycle arrest at the S phase. Docking in the CDK2 active site and pharmacophore modeling confirmed the affinity of 8b to the CDK2 active site. Absorption, distribution, metabolism, and excretion studies revealed that our target compounds are orally bioavailable, with no permeation through the blood–brain barrier.

中文翻译:

作为凋亡诱导剂的新型芳基唑并吡唑的合成:抑制 MCF-7 细胞增殖的候选药物

设计并合成了新的 4-芳基-3,5-二氨基-1H-吡唑衍生物在4-芳基环中被乙酰基部分取代。研究了新型芳基唑并吡唑对 MCF-7 细胞系的抗增殖活性。在所有目标化合物中,与参考标准伊马替尼 (IC50 7.0 µM) 相比,8b (IC50 3.0 µM) 和 8f (IC50 4.0 µM) 显示出更高的细胞毒性。通过抗 CDK2 激酶活性,对我们文库中最活跃的命中对象 8b 进行了进一步研究以探索作用机制。与伊马替尼相比,它对 CDK2 显示出良好的抑制作用 (IC50 0.24 µM),抑制率为 62.5%。MCF-7 细胞系的细胞周期分析显示 8b 诱导细胞凋亡,细胞周期停滞在 S 期。CDK2 活性位点的对接和药效团建模证实了 8b 对 CDK2 活性位点的亲和力。吸收、分布、代谢和排泄研究表明,我们的目标化合物具有口服生物利用度,不会透过血脑屏障。
更新日期:2020-09-13
down
wechat
bug